(NewsDirect)
Addex Therapeutics co-founder and CEO TimDyer speaks to Thomas Warner from Proactive about the work that thecentral nervous system-focused clinical-stage pharmaceutical companyhas been doing in the promising area of allosteric modulation.
He explains that company is currentlycollaborating with Johnson & Johnson on a phase two study forepilepsy, with results expected in Q2 of the following year.Additionally, Addex is developing treatments for chronic cough,schizophrenia, and cognition, with the latter receiving a grant fromthe European Union.
Dyer explainsthat the company's unique approach to allosteric modulation offersa competitive edge in drug discovery, setting them apart fromcompetitors. Their long-term strategy revolves around advancing theirprograms and securing partnerships to ensure steady cash inflows,especially given the challenging capital marketenvironment.
With seven programs in the pipeline and two alreadypartnered, Addex is poised for significant growth in the coming years.Dyer says that "at the moment we continue to move the programsforward... we're very focused today on securing cash inflows tokeep the business going through partnerships."
ContactDetails
Proactive United States
ProactiveUnited States
+1 347-449-0879
Copyright (c) 2023 TheNewswire - All rights reserved.